{
    "clinical_study": {
        "@rank": "110789", 
        "arm_group": {
            "arm_group_label": "stage 3 or stage 4 meibomiang gland dysfunction patients", 
            "description": "stage 3 or stage 4 meibomiang gland dysfunction patients"
        }, 
        "brief_summary": {
            "textblock": "Ocular aberration may play a role in determining optical quality. Recently performed study\n      reported that ocular aberration of preocular tear film would be important factor in not only\n      diagnosing the dry eye but also determining the efficacy of treatment. Therefore, in this\n      study, the investigators will aim to prove the improvement of quality of vision via ocular\n      aberration changes indirectly after the proper treatment for moderate and severe meibomian\n      gland dysfunction. Also, the investigators will evaluate the changes of keratometric values\n      after treatment for moderate and severe meibomian gland dysfunction, which could be\n      demonstrated by autokeratometry, IOLMaster, Pentacam, and iTrace."
        }, 
        "brief_title": "Changes of Keratometric Value and Ocular Aberration After Treatment of Meibomian Gland Dysfunction", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Moderate and Severe Meibomiang Gland Dysfunction (Stage 3 or Stage 4 Meibomiang Gland Dysfunction)", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        (1) stage 3 or 4 meibomian gland dysfunction\n\n        Exclusion Criteria:\n\n          1. history of previous ocular or intraocular surgery\n\n          2. ocular infection, non dry eye ocular inflammation, ocular allergy, autoimmune\n             disease,\n\n          3. history of intolerance or hypersensitivity to any component of the study medications,\n\n          4. wearing contact lenses during the study period, presence of current punctal\n             occlusion,\n\n          5. pregnancy, lactating women, and children.\n\n          6. Additionally, patients were excluded if they were using any topical ocular or\n             systemic medication that could be used for the treatment MGD or dry eye, including\n             topical or oral antibiotics, topical cyclosporine A, topical or oral steroids,\n             topical non-steroidal anti-inflammatory drugs, topical ocular allergy medications or\n             artificial tears"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "stage 3 or stage 4 meibomiang gland dysfunction patients"
            }
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01692665", 
            "org_study_id": "1-2012-0031"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "meibomian gland dysfunction", 
            "keratometric value", 
            "ocular aberration"
        ], 
        "lastchanged_date": "February 17, 2014", 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Changes of keratometric value and ocular aberration", 
            "safety_issue": "No", 
            "time_frame": "a minimum of four minutes, once or twice dailybefore treatment, after 1 month, and after 2 months of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01692665"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}